(Information sent by the signatory company)
Toronto, March 25
It has been performed in heterogeneous xenograft models of triple-negative breast cancer derived from patients
ProteinQure, the leading startup in the computational design of peptide drugs, announces a major advance in the fight against triple negative breast cancer (TNBC). The novel peptide drug conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a broad set of patient-derived xenograft (PDX) models. The experiments were carried out in the laboratory of Dr David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world’s top five cancer research centres. Developed using ProteinQure’s cutting-edge computational platform, the Innovative PDC targeting SORT1 is a novel peptide linked to a highly potent chemotherapeutic agent. The drug candidate was tested in a wide range of breast cancer models. The results demonstrated notable antitumor efficacy, even in cancers resistant to standard chemotherapies and antibody-drug conjugates.” The collaboration with the David Cescon laboratory of the UHN has been decisive in validating the efficacy of our new PDC against one of the forms “Based on these results, we are advancing our lead program toward IND-Enabling studies and our first clinical trial,” said Lucas Siow, CEO of ProteinQure. “These findings not only highlight the power of our computational drug design platform, but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery.” ProteinQure collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, is the perfect setting to share these findings with the global community of cancer researchers. “We are excited to present these data at the AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups,” said Dr. David Cescon, head of the UHN laboratory. “The success of this unique PDC in various PDX models is a testament to the potential of combining advanced computational techniques, precision oncology and the robust preclinical platform of our laboratories.” Part of this work has been funded by the IRAP-Canada and the INOVAIT at Sunnybrook Hospital.Poster Presentation Details: Title: In Vivo Efficacy of a Novel Peptide-Conjugated Drug in Patient-Derived Breast Cancer Xenograft Models. Session Title: New Goals Date and Time: Tuesday, April 9 at 1:30 p.m. PT/4:30 p.m. ET Abstract Number: 5911 Speaker: Mitchell Elliott, UHN Princess Margaret Cancer CentreAbout ProteinQure ProteinQure is a pioneering company specializing in the computational design of peptide drugs using the most advanced artificial intelligence and molecular simulation technologies. Focused on precision medicine, ProteinQure is dedicated to transforming the drug development landscape and ushering in a new era of effective targeted treatments.About the David Cescon Lab at UHN The David Cescon Lab at the University Health Network is leader in breast cancer research and focuses on mechanisms of cancer progression and resistance to therapy. Through collaborations and cutting-edge preclinical and clinical research, the laboratory develops novel therapeutic strategies aimed at improving outcomes for cancer patients around the world.
Contact Contact name: ProteinQure Contact description: ProteinQure Contact phone: 1 437-779-8504
